Which has better valuation & earnings, CRBP or ENTX?

Entera Bio is trading at a lower price-to-earnings ratio than Corbus Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Corbus Pharmaceuticals N/A N/A -$78.54M -$6.19 N/A Entera Bio N/A N/A -$11.44M -$0.35 N/A

Is CRBP or ENTX more profitable?

Corbus Pharmaceuticals' return on equity of -87.05% beat Entera Bio's return on equity. Company Net Margins Return on Equity Return on Assets Corbus Pharmaceuticals N/A -87.05% -74.22% Entera Bio N/A -147.19% -103.22%

Does the media favor CRBP or ENTX?

In the previous week, Corbus Pharmaceuticals had 3 more articles in the media than Entera Bio. MarketBeat recorded 4 mentions for Corbus Pharmaceuticals and 1 mentions for Entera Bio. Corbus Pharmaceuticals' average media sentiment score of 0.34 beat Entera Bio's score of 0.30 indicating that Corbus Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Corbus Pharmaceuticals 1 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Entera Bio 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media prefer CRBP or PROK?

In the previous week, Corbus Pharmaceuticals had 1 more articles in the media than ProKidney. MarketBeat recorded 4 mentions for Corbus Pharmaceuticals and 3 mentions for ProKidney. Corbus Pharmaceuticals' average media sentiment score of 0.34 beat ProKidney's score of 0.18 indicating that Corbus Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Corbus Pharmaceuticals 1 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral ProKidney 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media prefer CRBP or ARVN?

In the previous week, Arvinas had 1 more articles in the media than Corbus Pharmaceuticals. MarketBeat recorded 5 mentions for Arvinas and 4 mentions for Corbus Pharmaceuticals. Corbus Pharmaceuticals' average media sentiment score of 0.34 beat Arvinas' score of 0.22 indicating that Corbus Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Corbus Pharmaceuticals 1 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Arvinas 1 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media prefer CRBP or RGNX?

In the previous week, REGENXBIO had 1 more articles in the media than Corbus Pharmaceuticals. MarketBeat recorded 5 mentions for REGENXBIO and 4 mentions for Corbus Pharmaceuticals. REGENXBIO's average media sentiment score of 1.79 beat Corbus Pharmaceuticals' score of 0.34 indicating that REGENXBIO is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Corbus Pharmaceuticals 1 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral REGENXBIO 1 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Does the media prefer CRBP or KMDA?

In the previous week, Kamada had 3 more articles in the media than Corbus Pharmaceuticals. MarketBeat recorded 7 mentions for Kamada and 4 mentions for Corbus Pharmaceuticals. Corbus Pharmaceuticals' average media sentiment score of 0.34 beat Kamada's score of 0.11 indicating that Corbus Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Corbus Pharmaceuticals 1 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Kamada 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Corbus Pharmaceuticals (CRBP) Competitors

$5.76 -0.09 (-1.45%)

As of 02:32 PM Eastern

Compare

CRBP vs. ENTX, PROK, ARVN, RGNX, and KMDA

Should you buy Corbus Pharmaceuticals stock or one of its competitors? Corbus Pharmaceuticals's main competitors and comparable companies include Entera Bio (ENTX), ProKidney (PROK), Arvinas (ARVN), REGENXBIO (RGNX), and Kamada (KMDA). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Corbus Pharmaceuticals compare to Entera Bio?

Corbus Pharmaceuticals (NASDAQ:CRBP) and Entera Bio (NASDAQ:ENTX) are both small-cap healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their analyst recommendations, valuation, dividends, media sentiment, institutional ownership, profitability, earnings and risk.

Entera Bio is trading at a lower price-to-earnings ratio than Corbus Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Corbus Pharmaceuticals	N/A	N/A	-$78.54M	-$6.19	N/A
Entera Bio	N/A	N/A	-$11.44M	-$0.35	N/A

Corbus Pharmaceuticals presently has a consensus price target of $41.00, suggesting a potential upside of 600.85%. Entera Bio has a consensus price target of $9.60, suggesting a potential upside of 266.41%. Given Corbus Pharmaceuticals' higher possible upside, equities research analysts clearly believe Corbus Pharmaceuticals is more favorable than Entera Bio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Corbus Pharmaceuticals	2 Sell rating(s)	0 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.60
Entera Bio	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.83

Corbus Pharmaceuticals' return on equity of -87.05% beat Entera Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Corbus Pharmaceuticals	N/A	-87.05%	-74.22%
Entera Bio	N/A	-147.19%	-103.22%

In the previous week, Corbus Pharmaceuticals had 3 more articles in the media than Entera Bio. MarketBeat recorded 4 mentions for Corbus Pharmaceuticals and 1 mentions for Entera Bio. Corbus Pharmaceuticals' average media sentiment score of 0.34 beat Entera Bio's score of 0.30 indicating that Corbus Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Corbus Pharmaceuticals	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Entera Bio	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Corbus Pharmaceuticals has a beta of 2.63, meaning that its share price is 163% more volatile than the broader market. Comparatively, Entera Bio has a beta of 1.4, meaning that its share price is 40% more volatile than the broader market.

64.6% of Corbus Pharmaceuticals shares are owned by institutional investors. Comparatively, 14.1% of Entera Bio shares are owned by institutional investors. 3.5% of Corbus Pharmaceuticals shares are owned by company insiders. Comparatively, 10.6% of Entera Bio shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Summary

Corbus Pharmaceuticals beats Entera Bio on 9 of the 14 factors compared between the two stocks.

How does Corbus Pharmaceuticals compare to ProKidney?

Corbus Pharmaceuticals (NASDAQ:CRBP) and ProKidney (NASDAQ:PROK) are both small-cap healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, earnings, media sentiment, institutional ownership, analyst recommendations, profitability, dividends and risk.

Corbus Pharmaceuticals has a beta of 2.63, indicating that its stock price is 163% more volatile than the broader market. Comparatively, ProKidney has a beta of 1.77, indicating that its stock price is 77% more volatile than the broader market.

ProKidney has higher revenue and earnings than Corbus Pharmaceuticals. ProKidney is trading at a lower price-to-earnings ratio than Corbus Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Corbus Pharmaceuticals	N/A	N/A	-$78.54M	-$6.19	N/A
ProKidney	$890K	536.70	-$68.99M	-$0.55	N/A

Corbus Pharmaceuticals presently has a consensus target price of $41.00, indicating a potential upside of 600.85%. ProKidney has a consensus target price of $12.00, indicating a potential upside of 659.49%. Given ProKidney's stronger consensus rating and higher possible upside, analysts clearly believe ProKidney is more favorable than Corbus Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Corbus Pharmaceuticals	2 Sell rating(s)	0 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.60
ProKidney	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.67

In the previous week, Corbus Pharmaceuticals had 1 more articles in the media than ProKidney. MarketBeat recorded 4 mentions for Corbus Pharmaceuticals and 3 mentions for ProKidney. Corbus Pharmaceuticals' average media sentiment score of 0.34 beat ProKidney's score of 0.18 indicating that Corbus Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Corbus Pharmaceuticals	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
ProKidney	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Corbus Pharmaceuticals has a net margin of 0.00% compared to ProKidney's net margin of -10,288.39%. ProKidney's return on equity of 0.00% beat Corbus Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Corbus Pharmaceuticals	N/A	-87.05%	-74.22%
ProKidney	-10,288.39%	N/A	-27.39%

64.6% of Corbus Pharmaceuticals shares are held by institutional investors. Comparatively, 51.6% of ProKidney shares are held by institutional investors. 3.5% of Corbus Pharmaceuticals shares are held by company insiders. Comparatively, 39.8% of ProKidney shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Summary

ProKidney beats Corbus Pharmaceuticals on 9 of the 16 factors compared between the two stocks.

How does Corbus Pharmaceuticals compare to Arvinas?

Corbus Pharmaceuticals (NASDAQ:CRBP) and Arvinas (NASDAQ:ARVN) are both small-cap healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their valuation, earnings, dividends, institutional ownership, profitability, analyst recommendations, risk and media sentiment.

Corbus Pharmaceuticals currently has a consensus price target of $41.00, indicating a potential upside of 600.85%. Arvinas has a consensus price target of $14.55, indicating a potential upside of 94.98%. Given Corbus Pharmaceuticals' stronger consensus rating and higher probable upside, research analysts plainly believe Corbus Pharmaceuticals is more favorable than Arvinas.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Corbus Pharmaceuticals	2 Sell rating(s)	0 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.60
Arvinas	2 Sell rating(s)	3 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.30

In the previous week, Arvinas had 1 more articles in the media than Corbus Pharmaceuticals. MarketBeat recorded 5 mentions for Arvinas and 4 mentions for Corbus Pharmaceuticals. Corbus Pharmaceuticals' average media sentiment score of 0.34 beat Arvinas' score of 0.22 indicating that Corbus Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Corbus Pharmaceuticals	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Arvinas	1 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Corbus Pharmaceuticals has a beta of 2.63, indicating that its stock price is 163% more volatile than the broader market. Comparatively, Arvinas has a beta of 1.8, indicating that its stock price is 80% more volatile than the broader market.

64.6% of Corbus Pharmaceuticals shares are owned by institutional investors. Comparatively, 95.2% of Arvinas shares are owned by institutional investors. 3.5% of Corbus Pharmaceuticals shares are owned by insiders. Comparatively, 7.3% of Arvinas shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Arvinas has a net margin of 2.94% compared to Corbus Pharmaceuticals' net margin of 0.00%. Arvinas' return on equity of 1.91% beat Corbus Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Corbus Pharmaceuticals	N/A	-87.05%	-74.22%
Arvinas	2.94%	1.91%	1.29%

Corbus Pharmaceuticals has higher earnings, but lower revenue than Arvinas. Corbus Pharmaceuticals is trading at a lower price-to-earnings ratio than Arvinas, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Corbus Pharmaceuticals	N/A	N/A	-$78.54M	-$6.19	N/A
Arvinas	$262.60M	1.83	-$80.80M	$0.10	74.60

Summary

Arvinas beats Corbus Pharmaceuticals on 9 of the 15 factors compared between the two stocks.

How does Corbus Pharmaceuticals compare to REGENXBIO?

Corbus Pharmaceuticals (NASDAQ:CRBP) and REGENXBIO (NASDAQ:RGNX) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, risk, profitability, dividends, analyst recommendations, valuation, institutional ownership and media sentiment.

Corbus Pharmaceuticals has a beta of 2.63, meaning that its share price is 163% more volatile than the broader market. Comparatively, REGENXBIO has a beta of 1.13, meaning that its share price is 13% more volatile than the broader market.

Corbus Pharmaceuticals has higher earnings, but lower revenue than REGENXBIO. REGENXBIO is trading at a lower price-to-earnings ratio than Corbus Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Corbus Pharmaceuticals	N/A	N/A	-$78.54M	-$6.19	N/A
REGENXBIO	$174.48M	2.94	-$193.88M	-$3.79	N/A

Corbus Pharmaceuticals has a net margin of 0.00% compared to REGENXBIO's net margin of -112.58%. Corbus Pharmaceuticals' return on equity of -87.05% beat REGENXBIO's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Corbus Pharmaceuticals	N/A	-87.05%	-74.22%
REGENXBIO	-112.58%	-220.07%	-46.04%

64.6% of Corbus Pharmaceuticals shares are owned by institutional investors. Comparatively, 88.1% of REGENXBIO shares are owned by institutional investors. 3.5% of Corbus Pharmaceuticals shares are owned by insiders. Comparatively, 14.2% of REGENXBIO shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

In the previous week, REGENXBIO had 1 more articles in the media than Corbus Pharmaceuticals. MarketBeat recorded 5 mentions for REGENXBIO and 4 mentions for Corbus Pharmaceuticals. REGENXBIO's average media sentiment score of 1.79 beat Corbus Pharmaceuticals' score of 0.34 indicating that REGENXBIO is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Corbus Pharmaceuticals	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
REGENXBIO	1 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Corbus Pharmaceuticals presently has a consensus price target of $41.00, indicating a potential upside of 600.85%. REGENXBIO has a consensus price target of $23.17, indicating a potential upside of 198.54%. Given Corbus Pharmaceuticals' higher possible upside, analysts clearly believe Corbus Pharmaceuticals is more favorable than REGENXBIO.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Corbus Pharmaceuticals	2 Sell rating(s)	0 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.60
REGENXBIO	1 Sell rating(s)	3 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.64

Summary

REGENXBIO beats Corbus Pharmaceuticals on 9 of the 15 factors compared between the two stocks.

How does Corbus Pharmaceuticals compare to Kamada?

Corbus Pharmaceuticals (NASDAQ:CRBP) and Kamada (NASDAQ:KMDA) are both small-cap healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their dividends, earnings, risk, profitability, media sentiment, analyst recommendations, institutional ownership and valuation.

Kamada has a net margin of 11.60% compared to Corbus Pharmaceuticals' net margin of 0.00%. Kamada's return on equity of 8.37% beat Corbus Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Corbus Pharmaceuticals	N/A	-87.05%	-74.22%
Kamada	11.60%	8.37%	5.85%

Corbus Pharmaceuticals currently has a consensus target price of $41.00, indicating a potential upside of 600.85%. Kamada has a consensus target price of $13.50, indicating a potential upside of 68.75%. Given Corbus Pharmaceuticals' higher probable upside, analysts plainly believe Corbus Pharmaceuticals is more favorable than Kamada.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Corbus Pharmaceuticals	2 Sell rating(s)	0 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.60
Kamada	0 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	3.00

In the previous week, Kamada had 3 more articles in the media than Corbus Pharmaceuticals. MarketBeat recorded 7 mentions for Kamada and 4 mentions for Corbus Pharmaceuticals. Corbus Pharmaceuticals' average media sentiment score of 0.34 beat Kamada's score of 0.11 indicating that Corbus Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Corbus Pharmaceuticals	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Kamada	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Corbus Pharmaceuticals has a beta of 2.63, meaning that its stock price is 163% more volatile than the broader market. Comparatively, Kamada has a beta of 0.89, meaning that its stock price is 11% less volatile than the broader market.

64.6% of Corbus Pharmaceuticals shares are owned by institutional investors. Comparatively, 20.4% of Kamada shares are owned by institutional investors. 3.5% of Corbus Pharmaceuticals shares are owned by company insiders. Comparatively, 36.1% of Kamada shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Kamada has higher revenue and earnings than Corbus Pharmaceuticals. Corbus Pharmaceuticals is trading at a lower price-to-earnings ratio than Kamada, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Corbus Pharmaceuticals	N/A	N/A	-$78.54M	-$6.19	N/A
Kamada	$180.46M	2.55	$20.20M	$0.38	21.05

Summary

Kamada beats Corbus Pharmaceuticals on 10 of the 15 factors compared between the two stocks.

Get Corbus Pharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CRBP and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

CRBP vs. The Competition

Export

Metric	Corbus Pharmaceuticals	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$107.64M	$3.82B	$7.12B	$13.44B
Dividend Yield	N/A	3.65%	2.54%	17.38%
P/E Ratio	-0.93	13.45	274.31	26.29
Price / Sales	N/A	1,219.45	596.38	86.16
Price / Cash	N/A	39.04	27.22	34.70
Price / Book	0.69	16.86	11.16	6.39
Net Income	-$78.54M	-$23.20M	$3.50B	$381.07M
7 Day Performance	-13.05%	-3.63%	-2.04%	-0.34%
1 Month Performance	-47.97%	-11.80%	-6.77%	-4.58%
1 Year Performance	-60.30%	15.03%	5.90%	1.48%

Corbus Pharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
CRBP Corbus Pharmaceuticals	3.0099 of 5 stars	$5.77 -1.5%	$41.00 +611.2%	-60.6%	$107.64M	N/A	N/A	36
ENTX Entera Bio	3.4378 of 5 stars	$2.89 -0.7%	$9.60 +232.2%	+37.9%	$506.11M	$40K	N/A	21
PROK ProKidney	1.6682 of 5 stars	$1.71 +3.0%	$12.00 +601.8%	-42.3%	$501.86M	$890K	N/A	231
ARVN Arvinas	2.7123 of 5 stars	$7.43 -4.0%	$14.55 +95.8%	-22.4%	$499.07M	$262.60M	74.31	246
RGNX REGENXBIO	2.9657 of 5 stars	$7.42 -1.5%	$23.27 +213.6%	-25.6%	$497.08M	$170.44M	N/A	371	News Coverage Analyst Upgrade

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:CRBP) was last updated on 10/6/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Corbus Pharmaceuticals (CRBP) Competitors

CRBP vs. ENTX, PROK, ARVN, RGNX, and KMDA

How does Corbus Pharmaceuticals compare to Entera Bio?

Summary

How does Corbus Pharmaceuticals compare to ProKidney?

Summary

How does Corbus Pharmaceuticals compare to Arvinas?

Summary

How does Corbus Pharmaceuticals compare to REGENXBIO?

Summary

How does Corbus Pharmaceuticals compare to Kamada?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CRBP vs. The Competition

Corbus Pharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Corbus Pharmaceuticals (CRBP) Competitors

CRBP vs. ENTX, PROK, ARVN, RGNX, and KMDA

How does Corbus Pharmaceuticals compare to Entera Bio?

Which has better valuation & earnings, CRBP or ENTX?

Do analysts recommend CRBP or ENTX?

Is CRBP or ENTX more profitable?

Does the media favor CRBP or ENTX?

Which has more volatility and risk, CRBP or ENTX?

Do insiders and institutionals hold more shares of CRBP or ENTX?

Summary

How does Corbus Pharmaceuticals compare to ProKidney?

Which has more volatility and risk, CRBP or PROK?

Which has better earnings and valuation, CRBP or PROK?

Do analysts prefer CRBP or PROK?

Does the media prefer CRBP or PROK?

Is CRBP or PROK more profitable?

Do institutionals and insiders believe in CRBP or PROK?

Summary

How does Corbus Pharmaceuticals compare to Arvinas?

Do analysts prefer CRBP or ARVN?

Does the media prefer CRBP or ARVN?

Which has more volatility & risk, CRBP or ARVN?

Do institutionals & insiders believe in CRBP or ARVN?

Is CRBP or ARVN more profitable?

Which has higher valuation and earnings, CRBP or ARVN?

Summary

How does Corbus Pharmaceuticals compare to REGENXBIO?

Which has more risk & volatility, CRBP or RGNX?

Which has stronger earnings & valuation, CRBP or RGNX?

Is CRBP or RGNX more profitable?

Do insiders and institutionals have more ownership in CRBP or RGNX?

Does the media prefer CRBP or RGNX?

Do analysts rate CRBP or RGNX?

Summary

How does Corbus Pharmaceuticals compare to Kamada?

Is CRBP or KMDA more profitable?

Do analysts recommend CRBP or KMDA?

Does the media prefer CRBP or KMDA?

Which has more volatility & risk, CRBP or KMDA?

Do institutionals & insiders have more ownership in CRBP or KMDA?

Which has better valuation & earnings, CRBP or KMDA?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CRBP vs. The Competition

Corbus Pharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools